| Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... The lancet oncology 21 (2), 207-221, 2020 | 726 | 2020 |
| Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Q Deng, G Han, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen, E Dai, ... Nature medicine 26 (12), 1878-1887, 2020 | 387 | 2020 |
| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 376 | 2021 |
| Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA G Palladini, E Kastritis, MS Maurer, J Zonder, MC Minnema, ... Blood, The Journal of the American Society of Hematology 136 (1), 71-80, 2020 | 207 | 2020 |
| ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies JO Ishizawa, K Kojima, D Chachad, P Ruvolo, V Ruvolo, RO Jacamo, ... Science signaling 9 (415), ra17-ra17, 2016 | 173 | 2016 |
| Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study S Lonial, HC Lee, A Badros, S Trudel, AK Nooka, A Chari, AO Abdallah, ... Cancer 127 (22), 4198-4212, 2021 | 119 | 2021 |
| A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE®(bispecific T-cell engager) molecule, in relapsed … SJ Harrison, MC Minnema, HC Lee, A Spencer, P Kapoor, D Madduri, ... Blood 136, 28-29, 2020 | 111 | 2020 |
| Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial Q Bashir, PF Thall, DR Milton, PS Fox, JD Kawedia, P Kebriaei, N Shah, ... The Lancet Haematology 6 (5), e266-e275, 2019 | 83 | 2019 |
| Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma X Zhang, HC Lee, F Shirazi, V Baladandayuthapani, H Lin, I Kuiatse, ... Leukemia 32 (10), 2224-2239, 2018 | 82 | 2018 |
| Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease H Liu, J He, SP Koh, Y Zhong, Z Liu, Z Wang, Y Zhang, Z Li, BT Tam, P Lin, ... Science translational medicine 11 (494), eaau9087, 2019 | 79 | 2019 |
| Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life E Terpos, J Mikhael, R Hajek, A Chari, S Zweegman, HC Lee, MV Mateos, ... Blood cancer journal 11 (2), 40, 2021 | 74 | 2021 |
| Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes HC Lee, RM Saliba, G Rondon, J Chen, Y Charafeddine, LJ Medeiros, ... Biology of Blood and Marrow Transplantation 21 (11), 1948-1954, 2015 | 73 | 2015 |
| RNA Polymerase I Inhibition with CX‐5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma HC Lee, H Wang, V Baladandayuthapani, H Lin, J He, RJ Jones, I Kuiatse, ... British journal of haematology 177 (1), 80-94, 2017 | 71 | 2017 |
| Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma J Zhuang, F Shirazi, RK Singh, I Kuiatse, H Wang, HC Lee, Z Berkova, ... Blood, The Journal of the American Society of Hematology 133 (14), 1572-1584, 2019 | 69 | 2019 |
| Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma HC Lee, NS Raje, O Landgren, VV Upreti, J Wang, AA Avilion, X Hu, ... Leukemia 35 (1), 255-258, 2021 | 59 | 2021 |
| Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma F Shirazi, RJ Jones, RK Singh, J Zou, I Kuiatse, Z Berkova, H Wang, ... Proceedings of the National Academy of Sciences 117 (33), 20004-20014, 2020 | 55 | 2020 |
| Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study PG Richardson, HC Lee, AO Abdallah, AD Cohen, P Kapoor, ... Blood cancer journal 10 (10), 106, 2020 | 46 | 2020 |
| Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein–Barr virus lytic cycle through phosphoinositide 3-kinase signaling and ikaros expression RJ Jones, T Iempridee, X Wang, HC Lee, JE Mertz, SC Kenney, HC Lin, ... Clinical Cancer Research 22 (19), 4901-4912, 2016 | 44 | 2016 |
| Subcutaneous daratumumab+ cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chain (AL) amyloidosis: primary results from the phase … E Kastritis, G Palladini, M Minnema, A Wechalekar, A Jaccard, H Lee, ... EHA25 Virtual Congress, 11-21, 2020 | 40 | 2020 |
| LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. HC Lee, N Bumma, JR Richter, MV Dhodapkar, JE Hoffman, ... Journal of Clinical Oncology 41 (16_suppl), 8006-8006, 2023 | 34 | 2023 |
